Site Audit and Overview

Site Audit and Overview

Site audit and overview in clinical trials involves an independent and systematic examination of trial-related activities and records to determine whether the evaluated activities were conducted and data were recorded, analysed and accurately reported according to the protocol, sponsor procedures, Good Clinical Practice (GCP) and applicable regulatory requirements.

Site audits form part of quality assurance and should be distinguished from routine clinical trial monitoring. The nature, scope and frequency of audits should be proportionate to the importance and risks of the trial activities being evaluated.

Purpose of a Site Audit

A site audit provides independent assurance about the quality and compliance of clinical trial activities conducted at an investigator site.

An audit may evaluate whether:

• Participant rights, safety and well-being are appropriately protected
• Trial activities comply with the protocol and applicable requirements
• Trial data and records are reliable
• Responsibilities are appropriately performed
• Significant quality or compliance issues are identified and addressed

Audit activities should support the overall quality-management approach for the clinical trial.

Risk-Based Audit Planning

Not every investigator site requires the same level or frequency of auditing.

Audit planning should consider factors such as:

• Importance and complexity of trial activities
• Risks to participant safety
• Risks to the reliability of trial results
• Previous quality or compliance concerns
• Significant protocol deviations
• Data-quality concerns
• Experience of the investigator site
• Findings from monitoring or other oversight activities

This allows audit resources to focus on areas where independent assurance is most valuable.

Current international expectations for quality management and auditing in clinical trials are described in the ICH E6 Good Clinical Practice guideline.

Independence of Auditing

Auditing should be independent of routine clinical trial operations and monitoring.

Auditors should be appropriately qualified and sufficiently independent of the activities being audited to provide an objective assessment.

This independence helps distinguish quality assurance through auditing from the sponsor’s routine monitoring and operational oversight activities.

Protocol Compliance

The audit may assess whether the investigator site conducted the trial according to the approved protocol.

Areas reviewed may include:

• Participant eligibility
• Required trial procedures
• Protocol deviations
• Study assessments
• Visit requirements
• Documentation of trial activities

Significant deviations should be evaluated for their potential effect on participant protection and the reliability of trial results.

Informed Consent and Participant Protection

The audit may review whether informed consent was appropriately obtained and documented before participants underwent trial-specific procedures.

The audit may also assess compliance with requirements intended to protect participants’ rights, safety and well-being.

Relevant IRB/IEC approvals, consent documents and participant-related records may be reviewed where appropriate.

Investigator and Site Staff Responsibilities

The qualifications, training and responsibilities of the investigator and relevant site personnel may be evaluated.

The audit may assess whether:

• Staff were appropriately qualified
• Responsibilities were appropriately assigned
• Trial personnel received relevant training
• The investigator provided appropriate oversight
• Site resources were adequate for the activities performed

Data Integrity and Trial Records

A site audit may evaluate whether trial data and records are accurate, complete, traceable and appropriately maintained.

Relevant records may include:

• Source records
• Case report forms
• Electronic data
• Essential records
• Data corrections
• Relevant system records

The audit may also assess whether computerized systems and data-handling processes support reliable trial data.

Safety Reporting

The audit may evaluate whether safety information was identified, documented, assessed and reported according to the protocol and applicable requirements.

This may include review of serious adverse event reporting, relevant follow-up information and other safety-reporting responsibilities applicable to the investigator site.

Investigational Product Accountability

Where investigational products are used, the audit may assess their management and accountability at the site.

Areas may include:

• Receipt
• Storage
• Dispensing
• Use
• Inventory records
• Reconciliation
• Return or final disposition

Records should permit appropriate reconstruction of investigational product handling at the site.

Essential Records and Documentation

The audit may assess whether essential records are complete, accessible, appropriately maintained and retained.

Records should support evaluation and reconstruction of trial conduct and demonstrate compliance with relevant requirements.

Appropriate controls should also protect records from unauthorised access, alteration or loss.

Audit Findings

Audit findings should be documented and communicated through appropriate processes.

Findings may be classified according to their significance and potential impact on participant protection, regulatory compliance or the reliability of trial results.

Significant findings should be appropriately evaluated and escalated.

Corrective and Preventive Actions

Where audit findings identify significant deficiencies, appropriate corrective and preventive actions (CAPA) may be required.

Actions should address relevant root causes rather than only correcting individual observations.

Implementation and effectiveness of corrective actions should be followed up where appropriate.

Audit Documentation

Audit activities should be appropriately documented.

An audit report should describe relevant observations and conclusions according to the sponsor’s audit procedures.

Where required, documentation that an audit occurred should be maintained as an essential record. Detailed audit reports are generally managed within the sponsor’s independent quality-assurance system and are not treated in the same manner as routine monitoring reports.

Audit Versus Monitoring

Auditing and monitoring serve different but complementary quality functions.

Monitoring involves ongoing sponsor oversight of trial conduct, participant protection and data reliability and may use on-site, remote and centralised approaches.

Auditing is an independent examination performed as part of quality assurance to evaluate whether trial activities and data comply with applicable requirements.

Keeping these functions distinct helps preserve the independence and objectivity of the audit process.

For more information about ongoing sponsor monitoring activities, see Routine Site Monitoring.

Importance of Site Audit and Overview

Site audit and overview supports independent evaluation of clinical trial quality and compliance.

A risk-based audit programme can identify important systemic or site-level deficiencies, support appropriate corrective action and provide assurance that trial activities protect participants and generate reliable results.

Auditing should complement—not replace—routine monitoring, investigator oversight and the sponsor’s broader quality-management activities.

You may be interested in the programs below: